Mercator snags FDA patent for blood-pressure drug delivery catheters

Mercator's micro-infusion catheters pulled in FDA patent protection.--Courtesy of Mercator

Mercator MedSystems pulled in a new FDA patent for its micro-infusion drug delivery devices for renal denervation and carotid body modulation procedures as a treatment for high blood pressure. This includes its Bullfrog catheter, which received a CE mark in Europe in March. Mercator recently completed a clinical feasibility study of the device in Germany to determine the effectiveness of lidocaine delivery to alleviate pain experienced during the procedures. The company reported "promising results" in four patients treated prior to energy-based renal denervation. Release

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…